Author

Klaus R. Herrlinger

Observed names: Herrlinger, Klaus, K Herrlinger, K. Herrlinger, K. R. HERRLINGER, Klaus Herrlinger

Observed institutions: Universitair Ziekenhuis Leuven, Robert Bosch Hospital, Essen University Hospital, European Crohn's and Colitis Organisation, Asklepios, Asklepios Kliniken Hamburg, Stiftung Universitätsmedizin Essen, KU Leuven

OpenAlex ID: A5080637646

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

2009 · Gert Van Assche, Axel Dignass, et al. · Journal of Crohn s and Colitis · 899

PDF

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations

2012 · Gert Van Assche, Axel Dignass, et al. · Journal of Crohn s and Colitis · 473

Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004

2022 · Andreas Sturm, Andreas Stallmach, et al. · Zeitschrift für Gastroenterologie · 83

Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline

2020 · Torsten Kucharzik, Axel U. Dignass, et al. · Zeitschrift für Gastroenterologie · 63

Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus

2010 · K. R. HERRLINGER, D. N. BARTHEL, et al. · Alimentary Pharmacology & Therapeutics · 50

Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2)

2024 · T. Kucharzik, A. Dignass, et al. · Zeitschrift für Gastroenterologie · 45

PDF

2024 · Andreas Sturm, Raja Atreya, et al. · Zeitschrift für Gastroenterologie · 38

PDF

Comparison of machine learning methods with logistic regression analysis in creating predictive models for risk of critical in-hospital events in COVID-19 patients on hospital admission

2022 · Aaron W. Sievering, Peter Wohlmuth, et al. · BMC Medical Informatics and Decision Making · 37

PDF

Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009

2023 · T. Kucharzik, A. Dignass, et al. · Zeitschrift für Gastroenterologie · 33

PDF

Twenty‐five years of biologicals in IBD: What´s all the hype about?

2021 · Klaus R. Herrlinger, Eduard F. Stange · Journal of Internal Medicine · 30

PDF

Retinal Vascular Occlusion after COVID-19 Vaccination: More Coincidence than Causal Relationship? Data from a Retrospective Multicentre Study

2022 · Nicolas Feltgen, Thomas Ach, et al. · Journal of Clinical Medicine · 23

PDF

Clinical outcome, risk assessment, and seasonal variation in hospitalized COVID-19 patients—Results from the CORONA Germany study

2021 · Nele Gessler, Melanie A. Gunawardene, et al. · PLoS ONE · 22

PDF

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations

2015 · Van Assche, Gert, Dignass, Axel, et al. · Zurich Open Repository and Archive (University of Zurich) · 21

PDF

Aktualisierte S3-Leitlinie Colitis ulcerosa

2019 · Torsten Kucharzik, Axel U. Dignass, et al. · Zeitschrift für Gastroenterologie · 20

Aktualisierte S3-Leitlinie Colitis ulcerosa

2019 · Torsten Kucharzik, Axel U. Dignass, et al. · Zeitschrift für Gastroenterologie · 14

Is Dementia Associated with COVID-19 Mortality? A Multicenter Retrospective Cohort Study Conducted in 50 Hospitals in Germany

2022 · Karel Kostev, Nele Gessler, et al. · Journal of Alzheimer s Disease · 10

PDF

Prognostic Impact of Acute Cardiovascular Events in COVID-19 Hospitalized Patients—Results from the CORONA Germany Study

2021 · Melanie A. Gunawardene, Nele Gessler, et al. · Journal of Clinical Medicine · 8

PDF

504 A Double-Blind, Double-Dummy, Randomized, Controlled, Multicenter Trial On the Efficacy and Safety of Azathioprine Vs mesalamine for Prevention of Clinical Relapses in Crohn's Disease Patients with Postoperative Moderate or Severe Endoscopic Recurrence

2008 · Walter Reinisch, Sieglinde Angelberger, et al. · Gastroenterology · 8

To STRIDE or not to STRIDE: a critique of “treat to target” in Crohn´s disease

2023 · Klaus R. Herrlinger, Eduard F. Stange · Expert Review of Gastroenterology & Hepatology · 7

Kurzfassung der aktualisierten S3-Leitlinie der DGVS und des Kompetenznetzwerkes CED zur Diagnostik und Behandlung des Morbus Crohn

2008 · J Hoffmann, F Autschbach, et al. · DMW - Deutsche Medizinische Wochenschrift · 6

PDF

High In-Hospital Mortality in SARS-CoV-2-Infected Patients with Active Cancer Disease during Omicron Phase of the Pandemic: Insights from the CORONA Germany Study

2023 · Francis Maren Konermann, Nele Gessler, et al. · Oncology Research and Treatment · 5

PDF

Arguments for and against Centralization in Oncologic Visceral Medicine

2017 · Tobias Keck, Klaus R. Herrlinger, et al. · Visceral Medicine · 5

PDF

Histoplasmose: seltene opportunistische Infektion bei HIV-Infektion

2012 · M. Escher, T. Kainikkara, et al. · DMW - Deutsche Medizinische Wochenschrift · 5

Segundo consenso europeo basado en evidencia sobre el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Parte 3: situaciones especiales (versión española)

2015 · G. van Assche, A. Dignass, et al. · Revista de Gastroenterología de México · 4

PDF

Standardtherapie der Colitis ulcerosa

2002 · K. Herrlinger, K. Fellermann, et al. · Der Internist · 4

Works count: 60

Citation count: 1,925

H-index: 14

I10-index: 16